Trending: Enel Dismisses Rumors Over Endesa Stake Sale
Enel is among the most mentioned companies across news items over the last 12 hours, according to Factiva data, after dismissing rumors of a potential sale of its stake in Spanish subsidiary Endesa. News website El Confidencial reported Tuesday that Repsol's Chairman Antonio Brufau met with Borja Prado, former chairman of Endesa, to analyze a potential takeover of the company. "Enel dismisses the rumors about Endesa as totally groundless," a spokesperson for the Italian company told Dow Jones in a statement. "Enel has no intentions of selling its stakes in Endesa, neither now nor in the future, as the company is a key asset for its strategy, and informs that there are no discussions at all on this topic." The energy group added there has never been a meeting between the managers of Enel and Repsol, nor with Borja Prado. Enel currently holds a 70.1% stake in Endesa. Dow Jones & Co. owns Factiva. (giulia.petroni)
(END) Dow Jones Newswires
July 04, 2023 10:09 ET (14:09 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track